Home › FDA Approves Expanded Use of Agilent Assay as Keytruda CDx for Cervical Cancer

FDA Approves Expanded Use of Agilent Assay as Keytruda CDx for Cervical Cancer

Jun 12, 2018

NEW YORK (GenomeWeb) – Agilent Technologies said after the close of the market on Tuesday that the US Food and Drug Administration has approved the Dako PD-L1 IHC 22C3 pharmDx assay for expanded use as a companion diagnostic test for Keytruda (pembrolizumab) for cervical cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

What's Popular?

In Molecular Diagnostics

  1. Cancer Genetics Cancels Planned Merger With NovellusDx

  2. Black Women With Breast Cancer Fare Worse, TAILORx Analysis Confirms at SABCS

    Premium

  3. Mobidiag, Autobio Diagnostics to Form Joint Venture in China

  4. Guardant Health to Develop Blood-Based CDx for AstraZeneca Drugs

  5. Exosome Diagnostics Suing Former Employee for IP Theft

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.